LiverHealth Archives

AASLD Voice of China | Dr. Liang Peng’s Team: Release of Clinical and Basic Research Results on Multiple Hepatitis B Studies, Preliminary Confirmation

By Mourabit Halima 2023.12.22

From November 10th to 14th, 2023, the annual international highlight event in the field of hepatology, the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting, is being held in Boston, USA. Dr. Liang Peng's team from the Third Affiliated Hospital of Sun Yat-sen University has had multiple research results included in the conference. One randomized controlled trial evaluated the safety and effectiveness of tenofovir alafenamide fumarate (TAF) treatment for hepatitis B "healthy" carriers, and preliminary results indicate that TAF is safe for this population, with a rapid decrease in HBV DNA after 24 weeks of antiviral therapy, especially in the HBeAg-negative group where the HBV DNA undetectable rate is high [1].

Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis

By Mourabit Halima 2023.12.21

🔍 Exploring the Complexities of Cirrhosis Treatment: Insights from Dr. Thomas Reiberger Welcome to the latest feature from Hepatology Digest, where we delve into the nuanced world of liver health. In our upcoming article, we're excited to present the esteemed Dr. Thomas Reiberger, a leading figure in hepatology, known for his extensive research and clinical expertise. Dr. Reiberger brings a wealth of knowledge to the table, particularly in the controversial use of Non-Selective Beta-Blockers (NSBBs) for treating cirrhosis. Join us as we navigate the complexities of this treatment, examining its benefits, challenges, and the heated debates it sparks in the medical community. Stay tuned for an enlightening journey through the lens of a distinguished expert. 🔗 Stay connected with Hepatology Digest for cutting-edge insights and discussions.

Dr. Lai Wei’s Team at Tsinghua Chang Gung: Latest Developments in the Nationwide “MAFLD Epidemiological Survey Research Project” on Health Check-up

By Mourabit Halima 2023.12.21

In 2020, the international expert consensus on metabolic dysfunction-associated fatty liver disease (MAFLD) proposed a new definition, suggesting MAFLD as a more appropriate term to describe liver diseases related to metabolic dysfunction. According to the latest standards, patients with liver fat deposition meet at least one of the following three criteria: overweight or obesity, type 2 diabetes, or the presence of metabolic dysfunction (if their weight is normal). To comprehensively understand the current status of MAFLD in China, promote awareness among medical professionals and patients, and increase the diagnosis rate of the disease, in 2022, the National Health Examination Population "MAFLD Epidemiological Survey Research Project," led by Dr. Lai Wei of Tsinghua University Affiliated Beijing Tsinghua Chang Gung Hospital and co-initiated by the China Liver Health Promotion Center, was successfully launched. The two latest research findings from the project have been included in the 2023 Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Dr. Lai Wei has been invited by the Hepatology Digest to provide a detailed introduction to these two studies, the content of which is shared below.

Dr. Hongfei Zhang’s Team: Latest Stage Data Revealed for China’s “Sprout” Project, Aiding Clinical Cure for Children with Chronic Hepatitis B

By Peter W. PENG 2023.12.21

Chronic hepatitis B is the leading cause of liver disease in Chinese children, posing a serious threat to their health. The "Sprout" project is China's first large-scale real-world study focusing on antiviral treatment for chronic hepatitis B in children. Led by Dr. Hongfei Zhang's team, with Shenzhen Third People's Hospital as the main center, the project is a charitable initiative initiated by the Beijing Chen Jumei Foundation. On November 10, 2023, the first day of the 2023 American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Dr. Hongfei Zhang's team from the Chen Jumei Medical Group presented the latest stage data of the "Sprout" project. The team's detailed introduction to the project and its progress is shared below.

Headline: AASLD Hot Updates on MASLD from the 2023 Annual Meeting

By Peter W. PENG 2023.12.21

On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on Metabolic Associated Fatty Liver Disease (MASLD). Chaired by conference president Professor Norah Terrault, the event featured presentations by Professor Phuc Le of the Cleveland Clinic Lerner College of Medicine, who discussed his team's model predicting the changing prevalence of liver diseases in the U.S. until 2050. Dr. Zobair Younossi, the Global NASH Council Chairman, presented the latest findings on the correlation between food insecurity and MAFLD in American adolescents. Additionally, Dr. Rohit Loomba shared insights into the renaming of Non-Alcoholic Fatty Liver Disease (NAFLD) and the challenges associated with it.

AASLD Interview丨Professor Jeffrey V. Lazarus: Clinical Management, Research Priorities, and Future Action Plans for MASLD

By Mourabit Halima 2023.12.14

The 2023 American Association for the Study of Liver Diseases (AASLD 2023) recently concluded in Boston, USA. metabolic dysfunction-associated steatotic liver disease (MASLD) was a key topic at the conference. In the "Healthy Liver, Healthy Lives" session, experts discussed how to reverse the global MASLD trend and what actions to take to address MASLD management challenges. Dr. Jeffrey V. Lazarus, head of the Health Systems Research Group at ISGlobal in Barcelona, Spain, attended the meeting and gave an interview to "Hepatology Digest" afterward. The interview video and the transcript in both English and Chinese are compiled below.